| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
In this study, to establish antiviral therapies against human T-cell leukemia virus type 1 (HTLV-1) infection for HTLV-1-infected individuals (carriers), we developed two candidate drugs that can eliminate HTLV-1 by targeting and killing HTLV-1-infected cells: "a recombinant protein", truncated Pseudomonas exotoxin fused to CCL17 (a CCR4 ligand) to target CCR4 frequently expressed on HTLV-1-infected cells, and "a recombinant vesicular stomatitis virus" lacking the G gene and instead encoding HTLV-1 receptor, neuropilin 1, to target HTLV-1 envelope protein specifically expressed on HTLV-1-infected cells. We tested whether these candidate drugs selectively eliminated such infected cells, leading to the control of HTLV-1 infection in vitro and in vivo. Our present findings strongly indicated the therapeutic potential of these candidate anti-HTLV-1 drugs.
|
